China's Delays In Approving Clinical Trials, Poor IPR Block Access To Innovative Drugs - EU Chamber Of Commerce
This article was originally published in PharmAsia News
Executive Summary
BEIJING - China's lengthy process in reviewing clinical trial applications, unpredictable schedule for updating the national catalog of reimbursable drugs, and lax protection of intellectual property rights are all blocking access for most Chinese citizens to the latest innovative medicines developed worldwide, according to a leader in the European Union Chamber of Commerce in China
You may also be interested in...
In Major Policy Turnaround, Chinese Premier's Office Lifts Restrictions On Foreign Investment In Hospitals
BEIJING - In a major new policy change as part of sweeping health system reforms slated to be introduced in stages through the year 2020, the Chinese premier's office, or State Council, is lowering decades-old barriers on foreign investment in and control of hospitals across the country
In Major Policy Turnaround, Chinese Premier's Office Lifts Restrictions On Foreign Investment In Hospitals
BEIJING - In a major new policy change as part of sweeping health system reforms slated to be introduced in stages through the year 2020, the Chinese premier's office, or State Council, is lowering decades-old barriers on foreign investment in and control of hospitals across the country
Protectionist Economic Policies Create Roadblocks For Foreign Companies In China, Says U.S. Treasury Secretary
BEIJING - As the U.S. Senate held hearings on the Chinese exchange rate and overall economic policies that are said to be underlying an immense trade imbalance and blocking American businesses from competing freely in China, Treasury Secretary Timothy Geithner outlined an array of new and potential countermeasures